Posted by AGORACOM-JC
at 8:15 AM on Monday, November 30th, 2020
Announced that as a follow up to its press release dated September 23rd, 2020, the Company has filed four patent applications for its BioCloudTM Technology.
Four patent applications have been filed, three with the U.S. Patent and Trademark Office and one with the Canadian Intellectual Property Office : SYSTEM AND METHOD FOR DETECTING AIRBORNE PATHOGENS
TORONTO, ON / November 30, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company”) a leader in smart buildings and smart cities through IoT, Cloud and SaaS technology is pleased to announce that as a follow up to its press release dated September 23rd, 2020, the Company has filed four patent applications for its BioCloudTM Technology.
Four patent applications have been filed, three with the U.S. Patent and Trademark Office and one with the Canadian Intellectual Property Office : SYSTEM AND METHOD FOR DETECTING AIRBORNE PATHOGENS.
“These patent applications address key attributes of our technology, which utilizes a combination of continuous air quality monitoring and a proprietary detection chamber to target and identify airborne pathogens to help create safer spaces,” says Paul Ghezzi, CEO Kontrol. “We are very proud of our team and the milestone this represents. Innovation is at the core of our operations and we continue to execute on our plans.”
About Kontrol BioCloud
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.
BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
About Kontrol Energy
Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in smart buildings and smart cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware and service solutions to its customers to improve energy management, air quality and deliver continuous emission monitoring.
Paul Ghezzi, Chief Executive Officer [email protected] or [email protected] Kontrol Energy Corp. 180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8 Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer (BioCloud) are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Posted by AGORACOM-JC
at 7:21 AM on Monday, November 30th, 2020
Announce the North American Re-Seller & Distribution Agreement with API Pharma (“API”) for its FDA EUA submitted Rapid Antigen Test and Rapid Antibody Test.
Empower’s KAI Medical Laboratory provided API significant scientific data through three months of clinical trials.
As a result, Empower and API are now able to sell these products with confidence, on an unlimited basis, to its customers and prospective customers nationwide in the United States and in European countries supporting CE mark approval.
VANCOUVER, BC / November 30, 2020 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the Southwest United States, a telemedicine platform and medical diagnostics laboratory is pleased to announce the North American Re-Seller & Distribution Agreement with API Pharma (“API”) for its FDA EUA submitted Rapid Antigen Test and Rapid Antibody Test.
Empower’s KAI Medical Laboratory (“KAI”) provided API significant scientific data through three months of clinical trials. As a result, Empower and API are now able to sell these products with confidence, on an unlimited basis, to its customers and prospective customers nationwide in the United States and in European countries supporting CE mark approval.
Furthermore, Empower and KAI are providing API with support for its Health Canada submission for its Rapid Antigen Detection Test (“RADT”)(COVID-19 Application For Authorization If Import Or Sale Of Medical Devices). Empower will have Canadian distribution rights upon Health Canada approval.
Steven McAuley, Chairman and CEO of Empower stated “Our society is experiencing unprecedented changes that are affecting how we go back to work, how we travel and how we might gain permission to interact with others. Testing protocols and testing products are becoming a part of our daily lives, and there are key differences between PCR, antigen and antibody tests. They are all important, irrespective of how potential vaccines come to market. Our company is leading and positioned to provide all of these important tests to the markets we serve.”
The global COVID-19 diagnostics market size is valued at USD 19.8 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 3.1% from 2021 to 2027. These tests are critical in the management of the ongoing COVID-19 pandemic for accurate diagnosis as well as for tackling the spread of the infection (https://www.grandviewresearch.com/industry-analysis/covid-19-diagnostics-market)
WHAT IS A RAPID ANTIGEN DETECTION TEST (RADT)?
An RADT is a rapid diagnostic test suitable for point-of-care testing that directly detects the presence or absence of an antigen. This distinguishes it from other medical tests that detect antibodies or nucleic acid, of either laboratory or point of care types.
WHAT IS AN ANTIBODY TEST?
An antibody test, also known as a serology test, looks for specific antibodies in your blood. This test is useful because it shows if someone has had the infection in the past, even if you had only mild symptoms.
One inherent advantage of an antigen test over an antibody test is that it can take time for the immune system to develop antibodies after infection begins, but the foreign antigen is present within a preliminary incubation period of five days or less.
GOVERNMENT OF CANADA – RADT’s WILL HAVE AN IMPORTANT ROLE TO PLAY
The Government of Canada website for the use of RADT stated the following”
“Potential characteristics of these tests (faster turnaround time, lower per-test cost, ability to do the test in a setting by non-professionals on a more frequent basis, amongst others) suggest that they will have an important role to play in the next phase of the response. It is important for the public health, infectious diseases experts and laboratory communities to identify the scenarios where the use of RADTs may further strengthen the public health response by expanding access to testing”
Rapid testing is critical to any strategy for containing COVID-19. It helps determine where the virus is spreading, who has immunity and how widely the virus has spread.
The COVID-Rapid Antigen Test determines who has the virus at present and is likely to be contagious. With >99% sensitivity for those who are contagious, the rapid results allow healthcare providers to make quick and accurate medical decisions.
The COVID-Rapid Antibody Test, which screens blood for antibodies, can allow hospitals and workplaces to identify people who were infected and may have already developed immunity. Studies have shown that one-third to one-half of those infected with COVID-19 are asymptomatic. As a result, serology tests help determine who can lead the way back to reopen businesses and work on the front lines of health care.
The COVID-Rapid line of tests are accurate and affordable so it can be used for testing large populations. America has no choice but to rapid test for COVID-19 so that governments, schools, and workplaces can test large groups of individuals, not just those who present with symptoms.
API PHARMA RADT DEMONSTRATED HIGHLY EFFECTIVE ON 3 CONTINENTS
API Pharma’s COVID-Rapid Antigen test has been tested and demonstrated to be highly effective on three continents. This is important as it demonstrates all the different strains of the virus will respond equally to the rapid antigen test. Clinical studies were carried out specifically in China, the United States and Poland.
PARTNERSHIP FURTHER SOLIDIFIES KAI MEDICAL FOOTHOLD IN COVID-19 TESTING SPACE
The clinical trials of API products performed a variety of studies including the precision, accuracy, sensitivity, and interfering substances, as well as, the efficacy of operators to perform the test accurately. These studies ensure that API-products meet industry standards for testing and will accurately identify COVID-19 positives as well as COVID-19 negatives.
Because of API’s focus on Rapid, Point-of-Care testing for both antibodies and antigens, in addition to Kai Medical’s extraordinary capacity to handle industry-standard turnaround times for RT-PCR testing, this partnership further solidifies Kai Medical’s foothold in the COVID-19 testing space.
Yoshi Tyler, President of KAI Medical Laboratory stated “We anticipate that, moving forward, there will be a focus on much more rapid and accurate point-of-care testing, in order to return to everyday life. Like the virus, our testing strategies must be adaptable. As we move forward, we continue to prioritize the best and most efficacious testing strategies.”
KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.
As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including movie and television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.
ABOUT API PHARMA
API Pharma (API) is an industry leader in designing and distributing rapid tests for a range of viruses and diseases, including rotovirus, influenza, hepatitis, herpes, HIV, and others.
API’s rapid COVID-19 test is nearly as simple as a home pregnancy test, requiring only a few drops of blood from a finger stick and a drop of reagent. Results are available in under 20 minutes and are simple to interpret: one line means negative, two lines means positive. The test has 97% sensitivity and 97% specificity, and API’s long experience with rapid tests makes it a reliable provider. API currently has approval to provide test kits to medical facilities in the U.S. and expects to have FDA approval for home use soon. The test is already in use in Europe.
ABOUT EMPOWER
Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.
ABOUT Kai Medical Laboratory
Our mission is to change healthcare through science & innovative quality care by providing value added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas).
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
Posted by AGORACOM-JC
at 7:26 AM on Friday, November 27th, 2020
CEO Scott Burton today issued the following statement regarding legislation that was introduced by the Federal Government to legalize single-event sports betting in Canada.
Vancouver, British Columbia–(November 27, 2020) – FansUnite Entertainment Inc. (CSE: FANS) (OTCQB: FUNFF) (“FansUnite” or the “Company”) CEO Scott Burton today issued the following statement regarding legislation that was introduced by the Federal Government to legalize single-event sports betting in Canada.
The proposed federal government legislation will give provinces and territories in Canada the discretion to offer single-event sports betting products and manage single-event sports betting either online or in a physical facility in their respective jurisdictions.
“We are pleased that the federal government has decided to introduce legislation to legalize single-event sports wagering in Canada,” said Scott Burton, CEO of FansUnite Entertainment. “This is the first important step to making sports betting competitive in this country, followed by the potential for outside operators to participate in the Canadian market. With our team and global experience in regulated jurisdictions, we are positioned to capitalize on this opportunity if and when it happens.”
About FansUnite Entertainment Inc.
FansUnite is a global sports and entertainment company focusing on technology related to regulated and lawful online gaming and other related products. FansUnite has produced a one of a kind complete iGaming platform, Chameleon Gaming Platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform includes products for pre-match betting, in-play betting, daily fantasy, content and a certified RNG to produce casino-style chance games. The platform operates multiple B2C brands and B2B software for the online gambling industry. FansUnite also looks to acquire technology platforms and assets with high-growth potential in new or developing markets.
For further information, please contact:
Prit Singh Investor Relations at FansUnite [email protected] (905) 510-7636
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD-LOOKING STATEMENTS: Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “believes,” “belief,” “expects,” “intends,” ”anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue” or similar expressions to be uncertain and forward-looking. Forward-looking statements may include, without limitation, statements relating to future outlook and anticipated events such as: the coming into force of legislation relating to the legalization of single-event sports betting in Canada;opportunities to participate in the Canadian market; FansUnite’s ability to strengthen its position in the Canadian market; opportunities available to FansUnite in Canadian markets; and future acquisitions of FansUnite. Forward-looking statements are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of FansUnite to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Such factors include, among other things, the enactment of enabling legislation and regulations in other provinces of Canada to facilitate iGaming and the enactment of federal legislation to permit single-event sports wagering (including the timing of such legislation and regulations being passed and proclaimed in force (if at all) and the terms and conditions imposed in such legislation and regulations on participants in the iGaming industry), the receipt by the Company of all relevant licences and approvals under the relevant legislation and regulations, and the rate of adoption of online gaming in Canada. Additional information regarding the risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s Non-Offering Prospectus dated March 27, 2020 filed on its issuer profile on SEDAR at www.sedar.com, and risks related to global pandemics, including the novel coronavirus (COVID-19) global health pandemic, and the spread of other viruses or pathogens and influence of macroeconomic developments. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The forward-looking statements in this news release are made as of the date of this release. FansUnite disclaims and does not undertake to update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
Posted by AGORACOM-JC
at 4:15 PM on Thursday, November 26th, 2020
Q3 Financial Highlights:
Total revenue of $15,116,369
Adjusted EBITDA of $127,976
Total assets of $48,687,541
Montreal, Quebec–(November 26, 2020) – Peak Positioning Technologies Inc. (CSE: PKK) (OTCQX: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, today announced its financial results and operating highlights for the three-month and nine-month periods ended September 30, 2020, highlighted by a record $15.1M revenue for the quarter. All amounts expressed are in Canadian dollars.
Q3 Financial Highlights:
Total revenue of $15,116,369
Adjusted EBITDA of $127,976
Total assets of $48,687,541
Historical Revenue and adjusted EBITDA Summary
Q3 2020
Q2 2020
Q1 2020
Q4 2019
Q3 2019
Revenue
$15,116,369
$7,263,504
$3,949,395
$4,357,467
$4,499,953
Expenses1
$14,988,393
$7,087,391
$3,777,350
$4,032,092
$3,781,226
Adjusted EBITDA2
$127,976
$176,113
$172,045
$325,375
$718,727
1 Expenses do not include interest, taxes, depreciation (including impairment of intangible assets) loss on extinction of debt, gain on bargain purchase and amortization
2 Adjusted EBITDA equals net income (loss) before finance costs, taxes, depreciation, amortization and impairment of intangible assets, loss on extinction of debt, gain on bargain purchase and amortization
Q3 Operating Highlights:
New Jinxiaoer Service Centres in Nanjing and Taiyuan
Equipment financing program powered by Cubeler Lending Hub in Xi’An
Launch of government-backed commercial lending Financial Centre powered by Cubeler Lending Hub in Jiangyin
First supply-chain financing related services, previously outsourced, provided through Gold River 2.0 platform
Third Quarter Financial and Operating Results Summary
“As we expected, the demand for our services, particularly as it pertains to the supply-chain, reached a new level in the third quarter, but we’re still very much in the early stages of our client acquisition plan in that vertical,” commented Peak Group CEO, Johnson Joseph. “The vast majority of our supply-chain financing business is still financing purchase orders placed with a few raw material suppliers by 200 or so manufacturers. The objective is to work our way down the transactional supply-chain where we can finance purchase orders placed with thousands of manufacturers and distributors by tens of thousands of retailers, and we began to see some of those transactions in the latter part of the quarter”.
“The financing services related to transactions between material suppliers and manufacturers that took place in Q3 were bundled with logistics services. We outsourced those services because we didn’t have the software system through which the purchase orders could be placed and some of the logistics services provided. But that’s in the process of changing. We spent the better part of a year making adjustments to Gold River to be able to provide those services ourselves, which should dramatically reduce our outsourcing expenses,” concluded Mr. Joseph.
The continued geographic expansion of Peak’s services certainly played a role in the increase in the quarterly revenue, but it’s really the demand from the supply-chain vertical itself, mostly in the cities where the financing services were already being provided, that has had the biggest impact on the revenue growth.
The revenue trajectory on which the Company now finds itself, combined with the impact that the re-emergence of its Gold River platform is expected to have on future outsourcing expenses, bolstered the Company’s 2021 profit repatriation plans. Peak therefore engaged with consultants and advisors during the quarter to begin implementing the mechanisms prescribed by the Chinese government for foreign companies to repatriate profits from their Chinese subsidiaries. Other than the aforementioned outsourcing expenses, fees paid out to consultants and advisors represented the biggest expenses for the Company in Q3.
In summary, the Company generated revenue of $15,116,369 for the three-month period and $26,329,268 for the nine-month period ended September 30, 2020, compared to $4,499,953 for the three-month period and $7,351,186 for the nine-month period ended September 30, 2019.
Total expenses before taxes for the quarter amounted to $15,505,739, compared to $4,998,367 for the same period in 2019. The net (after tax) loss for Q3 was $512,874 compared to $777,316 for the same period of 2019.
Full details of the Company’s third quarter 2020 financial results can be found in the Unaudited Condensed Interim Consolidated Financial Statements and Management’s Discussion and Analysis (MD&A) for the three-month and nine-month periods ended September 30, 2020 and 2019, which are available at www.sedar.com.
About Peak Positioning Technologies Inc.:
Peak Positioning Technologies Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating in China’s commercial lending industry. Peak’s subsidiaries use technology, analytics and artificial intelligence to create an ecosystem of lenders, borrowers and other participants in China’s commercial lending space where lending operations are conducted rapidly, safely, efficiently and with the utmost transparency. For more information: http://www.peakpositioning.com.
CHF Capital Markets Cathy Hume, CEO 416-868-1079 ext.: 251 [email protected]
Peak Positioning Technologies Inc. Johnson Joseph, President and CEO 514-340-7775 ext.: 501 [email protected]
This news release may include certain forward-looking information, including statements relating to business and operating strategies, plans and prospects for revenue growth, using words including “anticipate”, “believe”, “could”, “expect”, “intend”, “may”, “plan”, “potential”, “project”, “seek”, “should”, “will”, “would” and similar expressions, which are intended to identify a number of these forward-looking statements. Forward-looking information reflects current views with respect to current events and is not a guarantee of future performance and is subject to risks, uncertainties and assumptions. The Company undertakes no obligation to publicly update or review any forward-looking information contained in this news release, except as may be required by applicable laws, rules and regulations. Readers are urged to consider these factors carefully in evaluating any forward-looking information.
Posted by AGORACOM-JC
at 9:14 AM on Thursday, November 26th, 2020
Announced that its name change to Peak Fintech Group Inc. will be effective as of Tuesday December 1, 2020 and its securities will begin trading under that name as of that date.
The Company’s ticker symbol will remain “PKK” on the Canadian Securities Exchange and “PKKFF” on the OTCQX® Best Market.
Montreal, Quebec–(November 26, 2020) – Peak Positioning Technologies Inc. (CSE: PKK) (OTCQX: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, today announced that its name change to Peak Fintech Group Inc. will be effective as of Tuesday December 1, 2020 and its securities will begin trading under that name as of that date. The Company’s ticker symbol will remain “PKK” on the Canadian Securities Exchange and “PKKFF” on the OTCQX® Best Market.
About Peak Positioning Technologies Inc.:
Peak Positioning Technologies Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating in China’s commercial lending industry. Peak’s subsidiaries use technology, analytics and artificial intelligence to create an ecosystem of lenders, borrowers and other participants in China’s commercial lending space where lending operations are conducted rapidly, safely, efficiently and with the utmost transparency. For more information: http://www.peakfintechgroup.com
For more information, please contact:
CHF Capital Markets Cathy Hume, CEO 416-868-1079 ext.: 251 [email protected]
Peak Positioning Technologies Inc. Johnson Joseph, President and CEO 514-340-7775 ext.: 501 [email protected]
This news release may include certain forward-looking information, including statements relating to business and operating strategies, plans and prospects for revenue growth, using words including “anticipate”, “believe”, “could”, “expect”, “intend”, “may”, “plan”, “potential”, “project”, “seek”, “should”, “will”, “would” and similar expressions, which are intended to identify a number of these forward-looking statements. Forward-looking information reflects current views with respect to current events and is not a guarantee of future performance and is subject to risks, uncertainties and assumptions. The Company undertakes no obligation to publicly update or review any forward-looking information contained in this news release, except as may be required by applicable laws, rules and regulations. Readers are urged to consider these factors carefully in evaluating any forward-looking information.
Posted by AGORACOM-JC
at 4:31 PM on Wednesday, November 25th, 2020
PyroGenesis (PYR:TSX) recently UP-Listed to the TSX from the TSX Venture on the strength of some major sales agreements for its plasma torch technology. Specifically, PYR announced an $11.5M sales to the US Navy for systems on two aircraft carriers, as well as, a $25M + contract for use by one of the biggest high-tech aluminum smelters in the world.
Yesterday, PYR announced the signing of an initial plasma torch contract with a Major Iron Ore Producer. The initial sale amount of $1.8M (for just 1 unit) doesn’t come close to the size of the agreements above – but it follows the exact same game plan of starting small and finishing big, something the Company alluded to in the press release quote which stated the following;
“It is expected that future sales with this Client will include a separate continued after-sale services agreement. The Client is a multi-billion-dollar international producer of iron ore pellets, one of the largest in the industry, whose name will remain confidential for competitive reasons. The Client, which has committed to reduce its greenhouse gas (“GHG”) emissions, has over ten (10) plants, each possibly requiring up to 50 plasma torches.”
The math has not alluded investors, who first had a slew of their own questions which CEO Peter Pascali answered as part of this great interview.
Posted by AGORACOM-JC
at 3:42 PM on Wednesday, November 25th, 2020
Q32020 results reflect the following highlights:
Revenues of $8,149,427, an increase of 289% from $2,097,437 over the same period in Q3 2020;
Comprehensive income of $15,325,996 an increase of 16 times that posted in Q3 2019 – ($965,032);
Net income from operations before share-based expenses of $3.1MM vs ($1MM) posted over the same period in 2019;
Positive cash flow from operations for three and nine months 2020 of $2.4MM and $1.6MM respectively versus ($0.85MM) and ($2.8MM) over the same periods in 2019;
Gross margin of 67.9% an increase of 22.7% over the same period in Q3 2019;
Cash on hand at September 30, 2020 of $2,095,519 (December 31, 2019 – $34,431);
Backlog of signed contracts of $36.4MM.
Basic Earnings per Share (EPS) of $0.10 for Q3 2020 and $0.13 for 9 months ending 2020.
MONTREAL, Nov. 25, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (OTCQB: PYRNF) (FRA:8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch systems, is pleased to announce today its financial and operational results for the third-quarter ended September 30 th, 2020.
“We are happy to be announcing Q3 2020 financial results, which are simply historical. We have posted quarterly revenues of over $8MM which is more than we have posted for any full year in recent memory. This reflects the successful processing of the backlog of signed contracts which we have previously announced. As of this writing, we have also retired all significant debt and raised over $12MM in a bought-deal, leaving us with over $17MM of cash on hand, positioning us very well for the future,” said Mr. P. Peter Pascali, CEO and Chair of PyroGenesis. “Of note, net income from operations of $3.1MM (before share-based expenses) is quite significant, and when combined with the results from our strategic investment, has contributed to a basic EPS of $0.10 for the quarter, and basic EPS of $0.13 for the 9 months, both of which have exceeded previous guidance. We expect this trend to continue.”
Q32020 results reflect the following highlights:
Revenues of $8,149,427, an increase of 289% from $2,097,437 over the same period in Q3 2020;
Comprehensive income of $15,325,996 an increase of 16 times that posted in Q3 2019 – ($965,032);
Net income from operations before share-based expenses of $3.1MM vs ($1MM) posted over the same period in 2019;
Positive cash flow from operations for three and nine months 2020 of $2.4MM and $1.6MM respectively versus ($0.85MM) and ($2.8MM) over the same periods in 2019;
Gross margin of 67.9% an increase of 22.7% over the same period in Q3 2019;
Cash on hand at September 30, 2020 of $2,095,519 (December 31, 2019 – $34,431);
Backlog of signed contracts of $36.4MM.
Basic Earnings per Share (EPS) of $0.10 for Q3 2020 and $0.13 for 9 months ending 2020.
OUTLOOK
The third quarter continues to reflect the results of the strategic long term focusing/positioning which has been taking place over the past several years.
To date during 2020, PyroGenesis has with respect to:
(i) Business Segments:
a)
received significant payments under the $20MM+ contract with Drosrite International, thereby validating announcements made during 2019;
b)
established a relationship with a US based tunneling company for plasma torches;
c)
signed a contract for approx. $3MM with HPQ Nano Silicon Powders Inc, a wholly owned subsidiary of HPQ Silicon Resources Inc, to exploit the benefits of the novel PUREVAP™ Nano Silicon Reactor (NSiR) to make nano Silicon powder for the battery market,
d)
established a relationship with an OEM in North America with the intent to eventually supply powders for their 3D printing needs. This augments our relationship with Aubert & Duval, while at the same time de-risking our dependence on them;
e)
closed the long-awaited order of $11.5MM for the US Navy. This contract was for two plasma waste destruction systems, one for each ship in the US Navy’s two-ship build;
f)
established itself in the iron ore pelletization industry as a supplier of plasma torches geared to replacing existing fossil fuel burners and thereby reducing greenhouse gas (GHG) emissions. Interest is also gaining traction in other industries with GHG emissions reduction targets, and
(ii) Financials:
a)
retired a $3MM convertible debenture in full, and repaid all other term loans;
b)
benefited from early conversion of warrants maturing in 2021 and beyond of approx. $4MM;
c)
bought back approximately 1.3 million shares under a Normal Course Issuer Bid at an average price of approximately 0.75;
d)
increased the Company’s investment in HPQ, which has subsequently experienced a significant increase in market capitalization;
e)
posted profitable operations in Q3 2020 (even after a onetime non-cash charge of approx. $3MM for share based compensation);
f)
posted positive cash flow from operations; for three and nine months 2020 of $2.4 MM and $1.6MM respectively versus ($0.849 MM) and ($2.8MM) over the same periods in 2019;
g)
booked backlog of signed contracts of approx. $36.4MM as of November 25 th , 2020;
h)
closed a $12MM bought deal (oversubscribed by >100%);
i)
graduated to the most senior exchange in Canada, the Toronto Stock Exchange (TSX).
At the time of this writing, the Company is well positioned with a clean balance sheet, over $17MM in cash on hand, and a healthy backlog of approx. $36.4MM.
One of the most significant developments in 2020 is the emergence of the Company as a credible provider of GHG reducing technologies to the iron ore pelletization industry with its patented plasma torch process geared to replacing fossil fuel burners. The Company is not only well positioned to address this opportunity with iron ore pelletizers, but to also leveraging off of this first mover advantage in other industries which are also under pressure to reduce GHG emissions and are similarly using fossil fuel burners (such as the cement, aluminum and glass industries).
The Company is already repositioning its offerings to address the world-wide need for solution to reduce GHG emissions, and expects a significant increase in interest in its offerings as a result. The Company is selectively considering strategic alliances with technologies/technology providers which could accelerate this strategic focus with a goal to become a world leader in GHG emissions reduction. The Company has, as of November 25 th , 2020, approximately $6MM of in-the-money warrants and options expiring in 2020 and 2021. The Company also has over $50MM in tax loss carryforwards (roughly evenly distributed between federal and provincial obligations) which is not reflected as an asset on the balance sheet.
Financial Summary
Revenues PyroGenesis recorded revenue of $8,149,427 in the third quarter of 2020 (“Q3, 2020”), representing an increase of 289% compared with $2,097,437 recorded in the third quarter of 2019 (“Q3, 2019”). Revenues recorded during the nine months ended September 30, 2020 were generated primarily from:
(i) DROSRITE™ related sales of $6,384,563 (2019 – $Nil)
(ii) PUREVAP™ related sales of $2,883,819 (2019 – $328,733)
(iii) torch related sales of $897,822 (2019 – $1,932,353)
(iv) the development and support related to systems supplied to the U.S. Military of $478,132 (2019 – $500,946)
Cost of Sales and Services and Gross Margins Cost of sales and services before amortization of intangible assets was $2,610,119 in Q3 2020, representing an increase of 128% compared with $1,145,080 in Q3 2019, primarily due to an increase in employee compensation $530,860 (Q3, 2019 – $434,624), subcontracting $480,602 (Q3, 2019 – $79,579) and direct material $1,423,762 (Q3, 2019 – $516,552).
In Q3 2020, manufacturing overhead & other and foreign exchange increased to $198,351 (Q3, 2019 – $164,730). The gross margin for Q3 2020 was $5,532,526 or 67.9% of revenue compared to a gross margin of $947,090 or 45.2% of revenue for Q3 2019. As a result of the type of contracts being executed (the nature of project activity), as well as the composition of the cost of sales and services, the mix between labour, materials and subcontracts may be significantly different.
Investment tax credits recorded against cost of sales are related to projects that qualify for tax credits from the provincial government of Quebec. Qualifying tax credits decreased to $23,456 in Q3 2020, compared with $50,405 in Q3 2019. This represents a decrease of 53% year-over-year. In total, for the nine months, the Company earned refundable investment tax credits of $62,844 against cost of sales in Q3 2020. The Company continues to make investments in research and development projects involving strategic partners and government bodies.
The amortization of intangible assets of $6,782 in Q3 2020 and $5,267 for Q3 2019 relates to patents and deferred development costs. Of note, these expenses are non-cash items and will be amortized over the duration of their expected lives.
Selling, General and Administrative Expenses Included within Selling, General and Administrative expenses (“SG&A”) are costs associated with corporate administration, business development, project proposals, operations administration, investor relations and employee training.
SG&A expenses for Q3, 2020 were significantly impacted by a non-cash item, namely, share-based expenses as a result of the Company issuance of stock options to directors and employees which had an attributed expense value of $3,017,408 for Q3, 2020. SG&A (net of share-based expenses) were 28% of revenues in Q3 2020 (70%, of revenues in Q3 2019).
SG&A excluding the costs associated with share-based expenses (a non-cash item in which options vest over a four-year period), was $2,294,394 representing an increase of 54% compared with $1,485,803 reported for Q3, 2019. On a year-to-date basis, SG&A expenses before share-based expenses were $5,141,456 compared with $4,349,616 in the same period in 2019.
The increase in SG&A expenses in Q3, 2020 over the same period in 2019 is mainly attributable to the net effect of:
an increase of 76% in employee compensation, primarily due to an increase in commissions,
an increase of 59% for professional fees, primarily due to an increase in legal fees related to the uplisting to the TSX, accounting fees and patent expenses,
an increase of 91% in office and general expenses, is primarily due to an increase in computer, internet, security and safety expenses,
travel costs decreased by 91%, due to decrease in travel abroad,
depreciation on property and equipment decreased by 57%, primarily due to lower amounts of property and equipment being depreciated,
depreciation on right of use assets increased by 16% due to higher amounts of right of use assets being depreciated,
investment tax credits did not increase or decrease resulting in an unchanged variance,
government grants decreased by 100% due to lower level of activities supported by such grants and,
other expenses increased by 30%, primarily due to higher insurance expenses.
Separately, share based expenses increased by $3,017,408, or in Q3, 2020, over the same period in 2019 primarily as a result of stock options granted on July 16, 2020. This was directly impacted by the vesting structure of the stock option plan with 50% of the options vesting on the grant date requiring an immediate recognition of that cost.
For comparison purposes, had the vesting structure allocated 25% instead of 50% of the July 16, 2020 stock options granted on the grant date the share-based expenses would have resulted in an approximate amount of $2,500,000 a significant decrease of $517,408. Similarly had the vesting structure allocated 10% instead of 50% of the July 16, 2020 stock options granted on the grant date the share-based expenses would have resulted in an approximate amount of $1,150,000 a significant reduction of $1,867,408 in SG&A expenses. A comparative chart is provided below:
Share-based expenses with comparative structures
Structure
Expense
Actual
50%
$3,017,408
Hypothetical
25%
$ 2,500,000
Hypothetical
10%
$ 1,150,000
Research and Development (“R&D”) Costs The Company incurred $131,955 of net R&D costs in Q3, 2020, compared with $236,535 in Q3, 2019, representing a decrease of 44%. During the first nine months of fiscal 2020, net spending on internal R&D was $151,176 as compared to $544,954 in 2019, primarily due to an increase in government grants received of $366,254 in the nine months ending September 30, 2020 compared to $204,525 during the same period in 2019.
In addition to internally funded R&D projects, the Company also incurred R&D expenditures during the execution of client funded projects. These expenses are eligible for Scientific Research and Experimental Development (“SR&ED”) tax credits. SR&ED tax credits on client funded projects are applied against cost of sales and services (see “Cost of Sales” above).
Net Finance Costs Finance costs for Q3, 2020 totaled ($16,370) as compared with $246,352 for Q3, 2019, representing a decrease of 107%. The decrease in finance costs in Q3, 2020 is primarily attributable to the decrease in interest accretion on convertible liability instruments, and the decrease associated with the capitalized finance costs on borrowing costs as well as the retirement of debt. Of note, there is a Nil balance of convertible liability instruments at the end of Q3,2020.
Strategic Investments The adjustment to the fair market value of strategic investments in Q3 2020 resulted in a gain of $15,220,857 compared to a gain in the amount of $70,717 in Q3 2019, representing an increase of $15,150,140. The increase is primarily attributable to the increased market share value of common shares and warrants owned by the Company of HPQ Silicon Resources Inc.
NetComprehensive Loss The net comprehensive income for Q3 2020, of $15,325,996 compared to a loss of $965,032 in Q3 2019, represents an increase of $16,291,028. The difference of $16,291,028 in the comprehensive income in Q3 2020 is primarily attributable to the factors described above (net), which are summarized as follows:
(i)
an increase in product and service-related revenue of $6,051,990 in Q3 2020,
(ii)
an increase in product cost of sales and services totaling $1,466,554, primarily due to an increase in subcontracting and direct materials
(iii)
an increase of SG&A expenses of $3,811,850 in Q3, 2020 is primarily due to an increase in share-based payments, and employee compensation,
(iv)
a decrease in R&D expenses of $104,580 primarily due to a decrease in employee compensation, and an increase in government grants,
(v)
a decrease in net finance costs of $262,722 in Q3, 2020, primarily due to capitalized finance costs on borrowing costs and a decrease in accretion costs of convertible liability instruments,
(vi)
an increase of $15,150,140 in the fair market value of strategic investments.
EBITDA EBITDA in Q3, 2020 was $15,464,504 compared with an EBITDA loss of $556,963 for Q3, 2019, representing an increase of 2,877% year-over-year. The $16,021,467 increase in EBITDA in Q3 2020, compared with Q3 2019, is due to the increase in comprehensive income of $16,291,028, a decrease in depreciation on property and equipment of $25,833, an increase in depreciation of right of use assets of $17,479, an increase in amortization of intangible assets of $1,515 and a decrease in finance charges of $262,722.
Adjusted EBITDA in Q3, 2020 was $18,481,912 compared with an Adjusted EBITDA loss of $542,814 for Q3, 2019, representing an increase of 3,505%. The increase of $19,024,726 in the Adjusted EBITDA in Q3, 2020 is attributable to an increase in EBITDA of $16,021,467 and an increase of $3,003,259 in share-based payments.
Modified EBITDA in Q3, 2020 was $3,261,055 compared with a Modified EBITDA loss of $613,531 for Q3, 2019, representing an increase of 632%. The increase in the Modified EBITDA in Q3, 2020 is attributable to the increase in the Adjusted EBITDA of $19,024,726 offset by the increase in the change of fair value of investments of $15,150,140.
Liquidity The Company has incurred, in the last several years, operating losses and negative cash flows from operations, resulting in an accumulated deficit of $41,978,687 and a negative working capital of $4,712,539 as at Q3 2020, (December 31, 2019 – $60,237,656 and $10,492,102 respectively). Furthermore, as at Q3 2020, the Company’s current liabilities and expected level of expenses for the next twelve months exceed cash on hand of $2,095,519 (December 31, 2019 – $34,431). The Company has relied upon external financings to fund its operations in the past, primarily through the issuance of equity, debt, and convertible debentures, as well as from investment tax credits.
Revenue generated from active projects has begun to produce sufficient positive cash flow to fund operations. The Company has a strong backlog from signed contracts totaling $36.4MM, and a pipeline of prospective new projects resulting in the Company’s business plan becoming less dependent on raising additional funds to finance operations within and beyond the next 12 months. While the Company has been successful in securing financing in the past, raising additional funds is dependent on a number of factors outside the Company’s control, and as such there is no assurance that it will be able to do so, should it need to, in the future. If the Company is unable to obtain sufficient additional financing when needed, it may have to curtail operations and development activities, any of which could harm the business, financial condition and results of operations.
About PyroGenesis Canada Inc.
PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m 2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit www.pyrogenesis.com .
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com , or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the Toronto Stock Exchange (TSX), its Regulation Services Provider (as that term is defined in the policies of the TSX) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.
Posted by AGORACOM-JC
at 11:41 AM on Wednesday, November 25th, 2020
Recognized revenue of $7.6 million
Earned $362K excluding non cash expenses
Very strong balance sheet with $1.4M cash and $2M receivables
Introduced Naxalogy’s Social Media Automated Reporting Technologies.
Completed the second phase of a multi-phase R&D program through the Department of National Defence’s Innovation for Defence Excellence and Security IDEaS program.
Toronto, Ontario–(November 25, 2020) – Datametrex AI Limited(TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex“) is pleased to announce record third quarter 2020 (“Q3”) financial and operating results. All currency is in Canadian dollars, unless otherwise stated. All results are reported on a 100% basis.
The Company’s revenue increased by 189% in Q3 compared to the same period of last year. The Company’s cash position improved significantly to $1,413,374 compared to $119,675 at the end of 2019. The net loss improved with a decrease of 35% to ($451,353) compared to ($695,803) in the same period of last year. There was a $607,997 of option issuance expense and $194,517 of Depreciation and Amortization expense, which are non-cash based expenses.
Excluding these expenses, the Company generated a net profit. This is reflected in Adjusted EBITDA. The Adjusted EBITDA showed a significant improvement achieving a positive Adjusted EBITDA of $362,059, compared to ($539,116) in the same period of last year.
“In Q3 2020, the Company achieved multiple key milestones, a significant increase in gross revenue and improvement in its cash position. This positive outcome was a direct result of our quick response in implementing a plan to begin selling test kits as result of the global impact of the COVID-19 virus. This resulted in a substantial improvement to the bottom line,” said Marshall Gunter, CEO of the Company.
Business Outlook
AI and Technology
The Company is now targeting larger bids with the Canada’s Industrial and Technological Benefits (“ITB”) program that are in the range of tens of millions of dollar. At the same time, we are continuing to work with the United States Air Force (“USAF”), Office of Naval Reesarch (“ONR”) and the Defence Research and Development Canada (“DRDC”).
The Company is also continuing to expand its product and, as such, Nexalogy SMART technology will be available imminently on the market.
Our footprint in Korea continues to expand as demonstrated by the recent growth in our revenue. We are looking to bring the formula used in Korean sales to Canada and the United State for the private sector.
COVID-19 Test Kits
The Company continues to expand our footprint with film production companies and mining companies, performing approximately 5,000 tests a week. We expect the number of tests per week to grow continuously as the Company is now running tests in Vancouver, Toronto and Montreal.
Highlights for Q3 2020
Recognized revenue of $7.6 million for the nine-month 2020 period compared to $2.6 million in same period 2019, of which $4.9 million was earned in the third quarter.
The Company started securing and delivering purchase orders of COVID-19 test kits and generated $2.3 million COVID-19 related revenue in Q3 2020.
The Company has received $1.8 million from the exercise of share purchase warrants and options.
The Company introduced Naxalogy’s Social Media Automated Reporting Technologies.
The Company completed the second phase of a multi-phase R&D program through the Department of National Defence’s Innovation for Defence Excellence and Security IDEaS program.
Financial Highlights
The following table summarizes revenue, net loss and EBITDA* and Adjusted EBITDA* for the three and nine months ended September 30, 2020 and 2019.
* Note: EBITDA (non- IFRS measures) is calculated as Net Loss adjusted for 1. Income taxes, 2. Depreciation and amortization, and 3. Interest and accretion. Adjusted EBITDA (non-IFRS measures) is calculated as EBITFA adjusted for share based compensation.
Non-IFRS financial measures do not have standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Specific items may only be relevant in certain periods. For reconciliation of non-IFRS financial measures please refer to the Company’s Management Discussion and Analysis for the nine months ended September 30, 2020.
The Company’s Financial Statements and Management Discussion & Analysis (“MD&A”) are at SEDAR at www.sedar.com.
About Datametrex
Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational Health and Safety goals with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain.
Marshall Gunter – CEO Phone: (514) 295-2300 Email: [email protected]
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 7:33 AM on Wednesday, November 25th, 2020
5,044 patient visits generating total revenue of $629,854, compared to 5,807 patient visits generating $663,003 for Q3 2019.
17,457 patient visits generating total revenue of $2,306,111, compared to 11,304 patient visits generating $1,409,143 for nine months ended September 30, 2019.
VANCOUVER, BC / ACCESSWIRE / November 25, 2020 /EMPOWER CLINICS INC. (CSE:CBDT) (OTC PINK:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company”) has filed today its unaudited condensed interim financial statements and related management’s discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.
“Our Q3 2020 performance overall exceeded our expectations given the challenging operating environment in our key markets, yet the team managed to serve large quantities of patients while maintaining strict COVID-19 protocols for health and safety.” Said Steven McAuley, Chairman and CEO. “We also continue to implement numerous business development opportunities setting the stage for an exciting Q4 and 2021.”
Q3 2020 Highlights
5,044 patient visits generating total revenue of $629,854, compared to 5,807 patient visits generating $663,003 for Q3 2019.
Net loss of $460,035 or $0.00 per share, compared to a loss of $504,532 or $0.00 per share for Q3 2019, driven by increases in direct clinic costs as a percentage of revenue. This issue was addressed subsequent to the quarter by changing the compensation structure of the clinic’s physicians along with the implementation of further cost cutting measures in Arizona clinics.
Cash used in operating activities was $534,141, compared to $487,720 for Q3 2019.
Cash at September 30, 2020 of $112,539, compared to cash of $179,153 at December 31, 2019.
YTD 2020 Highlights
17,457 patient visits generating total revenue of $2,306,111, compared to 11,304 patient visits generating $1,409,143 for nine months ended September 30, 2019.
Net loss of $1,380,316 or $0.01 per share, compared to a loss of $2,359,579 or $0.02 per share for nine months ended September 30, 2019, driven by year to date increased profitability related to the Sun Valley Health acquisition and robust reductions in salaries and benefits, legal and professional fees and non-cash share-based payments expense.
Cash used in operating activities was $531,494, compared to cash used in operating activities of $1,819,670 for nine months end September 30, 2019.
Financial Performance for the nine months ended September 30, 2020
Increase in clinic revenues – The increase is attributed to the acquisition of Sun Valley in 2019 and the addition of 5 clinics for the full reporting period.
Increase in direct clinic expenses – This increase above prior year is attributable to the increase in number of patient visits and the related physician costs.
Decrease in loss from operations – This decrease in net loss from operations primarily attributable to an increase in clinic profitability with the acquisition of Sun Valley and a decrease in salaries and benefits, legal and professional fees and non-cash share-based payments expense.
Loss from operations for the quarter – The loss for the quarter is comparable to the loss for the same quarter in 2019. While able to reduce legal and professional fees for the quarter, there was an increase in direct clinic costs. This issue was addressed subsequent to the quarter by changing the compensation structure of the clinic’s physicians.
Please refer to the Company’s unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2020 and 2019, and accompanying Management Discussion and Analysis for a full review of the operations.
About Empower
Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the fact that Kai Medical Laboratory will complete the development of ABC RT-PCR test; the development of new accounts using the new test; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
